Viemed Healthcare, Inc.
VMDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeViemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company carries a $373.3M market cap, placing it firmly in the small-cap category. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
Market Cap
$373.3M
Beta
1.04
P/E (TTM)
27.22
P/E (Fwd)
24.50
EPS (TTM)
$0.36
EPS (Fwd)
$0.40
ROE
10.4%
ROA
8.2%
Cash
$10.7M
Total Debt
$11.6M
Free CF
$28.3M
52W Change
41.0%
Annual Financials
Cash vs Debt
Where VMD stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, VMD finished 4.24% below its 150-day moving average ($9.90) and 0.42% above its 200-day moving average ($9.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VMD overbought or oversold?
At the October 19, 2026 close, VMD's RSI(14) was 65.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $10.7M in cash, though total debt stands at $11.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $28.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 10.4%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $138.8M (2022) to $270.3M (2025), reflecting a 95% increase over the period.
As with any equity investment, VMD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. No single metric tells the full story. Reviewing VMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.